Otsuka Maryland Medicinal Laboratories, Inc.


Font Size:

Thank you for your interest in OMML. We're happy to answer questions about our company, and you can also find additional information on our website by clicking on these topics:

Please note that we cannot provide answers to personal medical questions. To obtain such answers you should contact your healthcare provider. Also note that this system is not designed to respond to product complaints.

For questions/comments regarding ABILIFY^� (aripiprazole) Tablets¹, call Bristol Myers Squibb, Co. at (800) 321-1335 toll free.

For questions/comments regarding PLETAL^� (cilostazol) Tablets², call Otsuka's Medical Affairs Department at (800) 441-6763 toll free.

For questions/comments regarding BreathTek^TM Urea Breath Test (UBT) for H. pylori Kits³ call (888) 637-3835 toll free.

For questions/comments regarding IV Busulfex^� (busulfan) Injection⁴call (800) 438-6141 toll free.

For questions/comments regarding SAMSCA^TM (tolvaptan)⁵ call (877) 7267220 toll free

For information regarding Otsuka's Polycystic Kidney Disease clinical trials, call (866) 712-5837

We are not currently enrolling additional patients in Otsuka's Hyponatremia clinical trials, however, please continue to monitor www.clinicaltrials.gov for future information

We are not currently enrolling additional patients in Otsuka's Dry Eye clinical trials, however, please continue to monitor www.clinicaltrials.gov for future information

Corporate Headquarters/General Inquiries
Otsuka Maryland Medicinal Laboratories, Inc.
Rockville, MD 20850 USA
(301) 424-9055 phone (800) 562-3974 toll free
(301) 424-9054 fax

Career Information/Resumes
Human Resources

Media Contact/Public Relations (U.S.)
Corporate Communications or by mail to:
Corporate Communications
Otsuka America Pharmaceutical, Inc.
2440 Research Boulevard Rockville, MD 20850 USA

OAPI Medical Information
(800) 441-6763

Questions About Otsuka Pharmaceutical Products (U.S. Residents Only)
Product Information

¹ Please see FULL PRESCRIBING INFORMATION including Boxed WARNINGS for ABILIFY.

² Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for PLETAL.

³Please see FULL PRESCRIBING INFORMATION for BreathTek.

⁴ Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for IV BUSULFEX.

⁵ Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for SAMSCA.

* OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.

0109W-0602